Bausch + Lomb IPO
Bausch + Lomb is a leading global eye health company focused on contact lenses, pharmaceuticals, and surgical products. The company has a strong portfolio of well-known brands and serves both consumer and professional markets. Investors value its established market position in the growing eye health sector and diverse product portfolio.
Key Facts
| Industry | Medical Devices & Eye Care |
| Founded | 1853 |
| Headquarters | Vaughan, Ontario, Canada |
| Employees | ~13,000 |
| Website | bausch.com |
| Funding | IPO in May 2022 at $18 per share |
About Bausch + Lomb
Bausch + Lomb is one of the world's oldest and most established eye health companies, manufacturing contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical equipment. The company operates across three main segments: contact lenses and lens care, ophthalmic pharmaceuticals for treating conditions like glaucoma and dry eye, and surgical devices including intraocular lenses and equipment for cataract and vitreoretinal procedures.
After being part of Bausch Health Companies (formerly Valeant), Bausch + Lomb was spun off and went public again in 2022, returning to its roots as an independent eye care company. The company has a significant global presence with manufacturing facilities worldwide and maintains strong relationships with eye care professionals. B+L continues to invest heavily in R&D, particularly in areas like myopia management and advanced surgical technologies, as the global population ages and eye care needs increase.
IPO Status
Bausch + Lomb completed its IPO in May 2022, trading on NYSE under the ticker BLCO. The company was spun off from Bausch Health Companies and priced its shares at $18, raising approximately $630 million. The IPO marked the return of the iconic eye care brand to public markets as an independent company. The separation from its former parent allowed Bausch + Lomb to focus specifically on eye health products and pursue its own growth strategy. Since going public, the company has worked to strengthen its market position and invest in innovation across its contact lens and pharmaceutical divisions.
Competitors
Frequently Asked Questions
Does Bausch + Lomb have a stock?
Yes, Bausch + Lomb completed its IPO in May 2022. The company trades on the New York Stock Exchange under the ticker symbol BLCO.
When is the Bausch + Lomb IPO date?
Bausch + Lomb already completed its IPO on May 6, 2022. The company is currently publicly traded and no longer has an upcoming IPO date.
How can I buy Bausch + Lomb stock?
You can buy Bausch + Lomb stock through any licensed brokerage account since it trades publicly on NYSE under the ticker BLCO. The stock is available during regular market hours through most online and traditional brokers.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts